Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.17%81 Interest Coverage is 107.47 as of Jun. 2026, which is 268% above its 10-year median of 29.19. GuruFocus rates SHSE:605507 with a GF Score™ of 81/100 and a GF Value™ of ¥15.68 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 678 Drug Manufacturers companies, Guobang Pharma ranks better than 68.14% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Guobang Pharma's
Operating Income
for the
three
months ended in Jun. 2026 was ¥213 Mil. Guobang Pharma's Interest Expense for the
three
months ended in Jun. 2026 was ¥-2 Mil.
Guobang Pharma's interest coverage for the quarter that ended in Jun. 2026 was 107.47.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Guobang Pharma's Interest Coverage or its related term are showing as below:
SHSE:605507'
s Interest Coverage Range Over the Past 10 Years
Min: 15.72 Med: 29.19 Max: 60.49
Current: 37.34
SHSE:605507's Interest Coverage is ranked better than 68.14% of 678
companies
in the Drug Manufacturers industry
Industry Median: 12.575
vs SHSE:605507: 37.34
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Guobang Pharma Interest Coverage Related Terms
Guobang Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a Interest Coverage of 107.47 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Guobang Pharma and its competitors. This is 268% above median its historical median of 29.19. Over the past decade, Guobang Pharma's Interest Coverage has ranged from 15.72 to 60.49. According to the industry distribution chart, Guobang Pharma ranks #216 out of 678 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is Guobang Pharma's Interest Coverage too high?
Guobang Pharma's current Interest Coverage of 107.47 is 268% above median its 10-year median of 29.19. Over the past 10 years, this metric has ranged from a low of 15.72 to a high of 60.49. The Drug Manufacturers industry median Interest Coverage is 12.58. Guobang Pharma's value of 107.47 is 754.6% above this industry median. Based on the distribution chart, Guobang Pharma ranks #216 out of 678 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #216 out of 678 companies for Interest Coverage. This puts Guobang Pharma in the upper half of its industry. The industry median Interest Coverage is 12.58. Guobang Pharma's value of 107.47 is 754.6% above this benchmark. Historically, Guobang Pharma's own Interest Coverage has ranged from 15.72 to 60.49 over the past decade. While the company's 10-year median is 29.19 vs. the industry median of 12.58, Guobang Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.58, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current Interest Coverage of 107.47 is 754.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current Interest Coverage is 107.47, which is 268% above median its own 10-year median of 29.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥15.68, compared to a current price of ¥17.76 — trading 13.3% above its estimated fair value. The current Interest Coverage is 107.47, which is 268% above median its 10-year median of 29.19 and 754.6% above the Drug Manufacturers industry median of 12.58. Guobang Pharma's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current Interest Coverage is 107.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥17.76 is trading 13.3% above its estimated GF Value™ of ¥15.68.
GuruFocus considers Guobang Pharma to be Modestly Overvalued.
Key valuation signals for SHSE:605507:
Interest Coverage: 107.47 (268% above median its 10-year median of 29.19)
GF Value™: ¥15.68 vs. price of ¥17.76 (13.3% above fair value)
Industry Position: 754.6% above the Drug Manufacturers median (#216 of 678)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
81GF Score
Get the complete analysis for SHSE:605507
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
